NCT06455514

Post-CA Neuroprotection With Magnesium

Neuroprotection Following Cardiac Arrest: A Randomized Control Trial of Magnesium

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 178 (estimated)
• Sponsor: NYU Langone Health · Academic / Other
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this pilot interventional study is to collect preliminary data on administering magnesium sulfate as a neuroprotective medication in patients who achieved Return of Spontaneous Circulation (ROSC) following Cardiac Arrest (CA). The primary aims are to assess the feasibility and safety of administering magnesium and measure serum markers of neuronal injury at prespecified time points in the post-cardiac arrest period. Because this is a pilot study with a limited sample size, the primary objective is to evaluate the precision and stability of the collected measures to inform the design and formal analysis in a larger trial.

Conditions

• Cardiac Arrest
• Return of Spontaneous Circulation

Interventions

Type	Name	Description
DRUG	Magnesium Sulfate	4 g of magnesium sulfate intravenously within 2 hours of Return of Spontaneous Circulation (ROSC), followed by a continuous drip (16 g) over 24 hours
DRUG	Saline	Control subjects will receive an equivalent volume of normal saline intravenously.

Timeline

• Start date: 2025-03-25
• Primary completion: 2026-03-30
• Completion: 2026-06-30
• First posted: 2024-06-12
• Last updated: 2026-04-07

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study